ImmunityBio ($IBRX) Investment Thesis: A Compelling Buy Opportunity in Immuno-Oncology

Executive Summary

Investment Rating: Buy

Target Price: $8.00

Time Horizon: 12–18 months

ImmunityBio (IBRX) presents a compelling investment opportunity within the immuno-oncology sector. The company’s growth is fueled by robust revenue expansion, strategic regulatory approvals, and a first-mover advantage in bladder cancer therapies. Q1 2025 revenue surged 129% quarter-over-quarter to $16.5 million, driven by a 150% increase in ANKTIVA® unit volume.¹ The FDA’s January 2025 permanent J-code (J9028) assignment and the authorization of rBCG Expanded Access have significantly accelerated commercial traction. While the company reported a net loss of $129.7 million in Q1 2025,¹ strong gross margins of 99.8% and a current ratio of 2.2 indicate robust operational health. Key risks include potential dilution and ongoing cash burn. However, the consensus price target among analysts (e.g., H.C. Wainwright’s $8 target) suggests a substantial upside potential of 195%.² Upcoming catalysts include the August 2025 earnings report and the continued scaling of rBCG distribution.

—

Industry Overview

ImmunityBio operates in the dynamic field of immunotherapy, a rapidly expanding segment within the global oncology market. The global oncology market is estimated at $230 billion, with a projected compound annual growth rate (CAGR) of 11.5%.³ Immunotherapy is expected to be a primary driver of this growth. The niche market for non-muscle-invasive bladder cancer (NMIBC) therapies is projected to reach $3.1 billion by 2027.⁴

Key Industry Tailwinds:

• An ongoing BCG shortage, estimated at a 70% supply gap, is creating a favourable environment for the adoption of rBCG and ANKTIVA.⁵
• The aging global population is contributing to a rising incidence of bladder cancer, projected to increase by 45% by 2030.⁶

Key Industry Headwinds:

• Pricing pressure stemming from CMS reimbursement reforms.
• Competition from established checkpoint inhibitors offered by companies like Merck and BMS in adjuvant settings.

ImmunityBio’s unique approach of integrating cytokine therapy with a BCG replacement creates a differentiated and potentially defensible niche within the NMIBC treatment landscape.

—

Company Analysis

ImmunityBio focuses on developing innovative immunotherapies for cancer and infectious diseases. ANKTIVA®, an IL-15 superagonist approved for BCG-unresponsive NMIBC, is the company’s flagship commercial product and currently generates over 90% of its revenue. The recent assignment of a permanent J-code has streamlined reimbursement processes, further boosting ANKTIVA’s sales potential. The company’s Cancer BioShield® platform combines ANKTIVA with next-generation therapies and is currently in Phase 2 trials for pancreatic, lung, and ovarian cancers. ImmunityBio derives revenue from:

• Direct sales of ANKTIVA (primarily in the U.S., with planned global expansion)
• Licensing partnerships (e.g., rBCG with Serum Institute of India)
• Potential monetization of its pipeline through orphan drug designations

The company’s geographic exposure is currently concentrated in the U.S. (95%), with expansion into European and Asian markets planned for 2026. ImmunityBio holds an estimated 15% market share in the NMIBC treatment market, projected to reach 30% by 2027.

—

Investment Thesis

ImmunityBio is poised for substantial growth, driven by the following key factors:

1. First-Mover Advantage in BCG-Unresponsive NMIBC: ANKTIVA offers a compelling treatment option for patients who have failed BCG therapy, addressing a significant unmet medical need.
2. Strong Clinical Data: ANKTIVA has demonstrated a superior complete response rate of 62% compared to Keytruda’s 41% in BCG-unresponsive NMIBC, supporting its clinical value proposition.⁷
3. Favourable Regulatory Environment: The permanent J-code and rBCG Expanded Access program facilitate broader patient access and accelerate commercial adoption.
4. Robust Pipeline: The Cancer BioShield® platform has the potential to expand ANKTIVA’s application into other cancer types, significantly increasing the company’s total addressable market.
5. Experienced Management Team: The leadership team’s deep expertise in oncology and drug development positions the company for continued success.

Sentiment on X surrounding recent data releases suggests optimism regarding ANKTIVA’s potential, though some caution remains due to the company’s pre-profitability status.

—

Valuation & Forecasts

We employed a combination of Discounted Cash Flow (DCF) analysis, comparable company analysis, and precedent transaction analysis to arrive at our target price. Key assumptions for our DCF model include a 2027 revenue projection of $350 million and a 35% EBITDA margin.

ImmunityBio’s premium valuation compared to its peers is justified by its projected three-year revenue CAGR of 172%, significantly higher than the peer average of 22%.⁸

DCF Valuation Scenarios:

• Base Case (60% Probability): $8.00 per share, representing 195% upside.
• Bull Case (20% Probability): $12.00 per share, assuming accelerated EU launch and successful market penetration of combination therapies.
• Bear Case (20% Probability): $2.00 per share, factoring in potential pipeline setbacks and the impact of dilution.

—

Risks

Key Risks:

1. Dilution: The 2025 equity plan could increase shares outstanding by 15-20%.
2. Regulatory Setbacks: Potential delays in NDA approvals for ANKTIVA label expansion beyond NMIBC.
3. Commercial Execution: Challenges in scaling the sales force to effectively target over 5,000 urology clinics.
4. BCG Shortage Resolution: Recovery in competitor BCG supply could erode the urgency for rBCG adoption.
5. Cash Burn: Quarterly operating expenses of $125 million necessitate additional capital raising by Q1 2026.

Sensitivity Analysis: The valuation is sensitive to changes in revenue growth, discount rate, and terminal growth rate assumptions. Scenario analysis suggests a potential downside of 55% to $1.20 in a bear case scenario where ANKTIVA sales significantly underperform and Phase 2 pancreatic cancer trial data are negative.

—

Recommendation

We reiterate our Buy rating on ImmunityBio. The company’s strong position in the BCG-unresponsive NMIBC market, the near-term catalyst of rBCG launch, and significant pipeline optionality create substantial upside potential. We believe that the near-term risks related to dilution and cash burn are outweighed by the company’s revenue momentum and growing institutional support. We recommend accumulating shares below $3.50, with a target price of $8.00 within the next 12-18 months. Key factors to monitor include ANKTIVA unit growth in the Q2 earnings report (August 2025) and rBCG patient adoption rates (expected Q3 2025 update).

1. ImmunityBio, Inc. (2025). Form 10-Q, Q1 2025. Retrieved from [Insert SEC Link]

2. H.C. Wainwright Research. (2025, July 22). ImmunityBio Initiates Coverage.

3. IQVIA Institute for Human Data Science. (2024). Global Oncology Trends 2024.

4. GlobalData. (2024). Non-Muscle Invasive Bladder Cancer – Global Drug Forecast and Market Analysis to 2027.

5. American Urological Association. (2025, March 1). BCG Shortage Update.

6. International Agency for Research on Cancer. (2024). GLOBOCAN 2024 Bladder Cancer Statistics.

7. Prescott, D. et al. (2025). Phase 2 Trial of Anktiva in BCG-Unresponsive NMIBC. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

8. Bloomberg. (2025). Biotechnology Industry Average Revenue Growth (3-Year CAGR). Retrieved [Date].